ARDELYX, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ARDELYX, INC. (ARDX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $730.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $368.00K, a 11.18% increase year-over-year.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $362.00K, a 60.78% decline year-over-year.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $357.00K, a 65.51% decline year-over-year.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $336.00K, a 67.06% decline year-over-year.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.95M, a 51.42% decline from fiscal 2024.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.01M, a 10.60% increase from fiscal 2023.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $3.62M, a 4.83% increase from fiscal 2022.
- ARDELYX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $3.46M, a 12.06% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $730.00K 10-Q · filed 2026-08-06 | $1.09M derived: sum of 3 quarters · filed 2026-08-06 | $1.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $362.00K 10-Q · filed 2026-04-30 | $719.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.05M derived: sum of 3 quarters · filed 2026-04-30 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $693.00K derived: sum of 2 quarters · filed 2026-02-19 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.95M 10-K · filed 2026-02-19 |
| 2025-09-30 | $336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $667.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.59M 10-Q · filed 2025-10-30 | $2.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.25M 10-Q · filed 2026-08-06 | $2.29M derived: sum of 3 quarters · filed 2026-08-06 | $3.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $923.00K 10-Q · filed 2026-04-30 | $1.96M derived: sum of 2 quarters · filed 2026-04-30 | $2.98M derived: sum of 3 quarters · filed 2026-04-30 | $3.98M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.06M derived: sum of 2 quarters · filed 2026-02-19 | $3.06M derived: sum of 3 quarters · filed 2026-02-19 | $4.01M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.02M derived: sum of 2 quarters · filed 2025-10-30 | $2.97M 10-Q · filed 2025-10-30 | $3.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $1.95M 10-Q · filed 2025-08-04 | $2.89M derived: sum of 3 quarters · filed 2026-02-19 | $3.76M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $948.00K 10-Q · filed 2025-05-01 | $1.88M derived: sum of 2 quarters · filed 2026-02-19 | $2.75M derived: sum of 3 quarters · filed 2026-02-19 | $3.67M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $934.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.80M derived: sum of 2 quarters · filed 2026-02-19 | $2.72M derived: sum of 3 quarters · filed 2026-02-19 | $3.62M 10-K · filed 2026-02-19 |
| 2023-09-30 | $869.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.79M derived: sum of 2 quarters · filed 2024-10-31 | $2.69M 10-Q · filed 2024-10-31 | $3.58M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.82M 10-Q · filed 2024-08-01 | $2.71M derived: sum of 3 quarters · filed 2025-02-20 | $3.58M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $902.00K 10-Q · filed 2024-05-02 | $1.79M derived: sum of 2 quarters · filed 2025-02-20 | $2.66M derived: sum of 3 quarters · filed 2025-02-20 | $3.52M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $887.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.76M derived: sum of 2 quarters · filed 2025-02-20 | $2.62M derived: sum of 3 quarters · filed 2025-02-20 | $3.46M 10-K · filed 2025-02-20 |
| 2022-09-30 | $872.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $1.73M derived: sum of 2 quarters · filed 2023-10-31 | $2.57M 10-Q · filed 2023-10-31 | $3.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $856.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.70M 10-Q · filed 2023-08-02 | $2.53M derived: sum of 3 quarters · filed 2024-02-22 | $3.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $842.00K 10-Q · filed 2023-05-03 | $1.67M derived: sum of 2 quarters · filed 2024-02-22 | $2.61M derived: sum of 3 quarters · filed 2024-02-22 | $3.32M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $828.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.77M derived: sum of 2 quarters · filed 2024-02-22 | $2.48M derived: sum of 3 quarters · filed 2024-02-22 | $3.08M 10-K · filed 2024-02-22 |
| 2021-09-30 | $939.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.65M derived: sum of 2 quarters · filed 2022-11-03 | $2.26M 10-Q · filed 2022-11-03 | $2.84M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $711.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.32M 10-Q · filed 2022-08-04 | $1.90M derived: sum of 3 quarters · filed 2023-03-02 | $2.44M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $607.00K 10-Q · filed 2022-05-05 | $1.19M derived: sum of 2 quarters · filed 2023-03-02 | $1.73M derived: sum of 3 quarters · filed 2023-03-02 | $2.25M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $579.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.12M derived: sum of 2 quarters · filed 2023-03-02 | $1.65M derived: sum of 3 quarters · filed 2023-03-02 | $2.15M 10-K · filed 2023-03-02 |
| 2020-09-30 | $543.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.07M derived: sum of 2 quarters · filed 2021-11-12 | $1.57M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.02M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $502.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $1.84M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |